Bifidobacterium Longum: Protection against Inflammatory Bowel Disease

Table 3

Clinical evidence for B. longum with IBD.

Strains	Number of patients (age)	Length of treatment	Dose	Effect	Ref.
B. longum 536	56 (31-58 years old)	8 weeks	CFU/day	Clinical remission; UC disease activity index ↓	[102]
B. longum ES1	16 (16-65 years old)	12 weeks	CFU/day	Proinflammatory cytokines ↓; Improved intestinal permeability	[103]
B. longum and synergy 1	35 (18-79 years old)	6 months	CFU/day	CD activity ↓; TNF-α ↓	[104]
B. longum and inuli	18 (24-67 years old)	4 weeks	4 × 10^11 CFU/day	Inflammatory parameters ↓	[105]
VSL #3	147 (26-52 years old)	12 weeks	CFU/day	Induction of remission in mild-to-moderate UC	[106]
VSL #3	119 (25-49 years old)	9 months	CFU/day	Inflammatory cytokine levels ↓	[107]
VSL #3	131 (33-62 years old)	8 weeks	CFU/day	Clinical scores in UC ↓	[109]
B. longum 536	12 (28-45 years old)	1 months	CFU/day	Improvement of gut microbiota	[112]